UrelixTM

Peptide-Enabling Technologies

Ureka’s proprietary UrelixTM technologies involve taking lead peptides and

optimize their pharmaceutical properties to generate the best drug candidates.

peptide-enabling-technologies-ureka

Foldamers

New Modalities in Drug Discovery

Foldamers are an emerging class of molecules with promising applications in drug discovery.

Urelix 1.0 - Peptide Engineering

UrelixTM

The UrelixTM approach consists of replacing a portion of a lead peptide with an oligourea segment to improve its pharmaceutical properties.

Smart and Simple

  • Easily accessible building blocks
  • Fully compatible with solid phase peptide synthesis
  • Applicable to any peptides
  • Fast results

Urelix 2.0 - Therapeutic Peptide

Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo

UrelixTM technologies were applied to GLP-1, an anti-diabetic peptide, to improve its action in vivo. See publication in Nature Communications here.

peptide-oligourea-hybrids-analogue-ureka

We Welcome

Collaborations

Do not hesitate to contact us if you think our technology

could be helpful for your projects.

Creating the Healthcare

of Tomorrow